Research & Development Tax Credits for Biotech and Life Sciences Companies
Federal and state tax credit opportunities for biotech, pharmaceutical, medical device, laboratory, and life sciences companies in the Greater Boston and Cambridge life sciences market.
Innovation in the life sciences industry can be expensive. In the Boston-Cambridge biotech ecosystem, companies may spend significant amounts on research programs, laboratory work, preclinical studies, clinical trials, product development, medical device design, regulatory testing, formulations, compounds, biologics, and proprietary scientific processes before revenue is ever generated.
The federal Research & Development Tax Credit was designed to encourage businesses to invest in new or improved products, processes, formulas, techniques, inventions, and technology. For life sciences companies, this may include qualified activities related to drug development, medical devices, diagnostics, laboratory testing, formulations, manufacturing processes, and technical experimentation.
Why the R&D Tax Credit Matters
The R&D tax credit can provide a dollar-for-dollar reduction of federal income tax. For eligible startups and qualified small businesses, a portion of the credit may also be available to offset certain employer payroll taxes. This can be especially valuable for early-stage life sciences companies that are investing heavily in research and development before becoming profitable.
The credit is not limited to successful projects. Failed experiments, abandoned compounds, rejected designs, unsuccessful prototypes, inconclusive testing, and technical alternatives may still be relevant when the company is attempting to resolve technical uncertainty through a process of experimentation.
R&D Tax Credits for Biotech and Life Sciences Companies
Biotech and life sciences companies often perform activities that may need to be reviewed for potential R&D credit opportunities. These may include developing new drug candidates, improving formulations, testing biologics, designing medical devices, developing diagnostics, improving laboratory methods, refining manufacturing processes, or evaluating technical alternatives.
The key issue is whether the work involves technical uncertainty and experimentation. A company may be uncertain about formulation, stability, performance, reliability, dosage, delivery method, safety, scalability, manufacturing process, testing method, or technical approach.
Routine quality control, ordinary testing, cosmetic changes, and non-technical business research generally do not qualify by themselves. However, testing performed as part of technical experimentation may be relevant.
Companies That May Benefit
A life sciences company may be a good candidate for an R&D credit review if it is involved in drug discovery, drug development, biologics, compounds, formulations, medical device design, diagnostics, preclinical studies, clinical trial support, regulatory testing, technical validation, laboratory methods, process development, or manufacturing scale-up.
Qualified Research Expenses
Qualified research expenses may include more than many companies expect. Depending on the facts, eligible costs may include employee wages for scientists, researchers, engineers, lab personnel, and technical supervisors performing, supervising, or supporting qualified research.
Other potential costs may include supplies used in experimentation, prototypes, testing materials, certain contract research expenses, laboratory testing, outside scientific consultants, CRO costs, and technical development costs connected to qualified research.
The key is not simply whether the company has an “R&D” account on its profit and loss statement. The key is whether the underlying activities meet the tax rules and whether the expenses can be reasonably supported.
Documentation and Project Tracking
Documentation is especially important for life sciences companies. Companies should be able to support what projects were worked on, what technical uncertainties existed, what experimentation was performed, who performed the work, and what costs were incurred.
Useful records may include project summaries, lab notebooks, payroll records, time allocations, general ledger detail, contractor invoices, CRO agreements, study protocols, testing results, formulation records, regulatory submissions, board reports, investor materials, and management summaries.
Federal and State R&D Credit Opportunities
In addition to the federal R&D tax credit, many states offer their own research and development credits or related incentives. This can be important for life sciences companies with research teams, laboratories, clinical activity, employees, or contractors in multiple states.
Massachusetts is especially important because of its concentration of biotech, pharmaceutical, medical device, laboratory, and life sciences companies in the Greater Boston and Cambridge market. Companies performing qualified research in Massachusetts may need to review whether a Massachusetts research credit opportunity exists.
Other states where R&D credit planning may be relevant include California, New York, New Jersey, Pennsylvania, Texas, Illinois, and other states where qualified research activities are performed.
Massachusetts Life Sciences Center Tax Incentives
For biotech and life sciences companies operating in the Greater Boston and Cambridge market, Massachusetts state incentives should be part of the tax planning discussion. The Massachusetts Life Sciences Center, commonly referred to as MLSC, administers programs designed to support life sciences research and development, commercialization, manufacturing, job creation, and long-term growth in Massachusetts.
The MLSC Tax Incentive Program supports companies engaged in life sciences research and development, commercialization, and manufacturing in Massachusetts. The program is designed to encourage companies of all sizes to expand in Massachusetts by creating new, long-term jobs.
More information is available directly from the Massachusetts Life Sciences Center at:
https://www.masslifesciences.com/programs/tax-incentive/
These incentives are not automatic. Companies generally must apply through MLSC, become certified as a life sciences company, meet program requirements, and receive an award before claiming the incentive. The program may be especially relevant for biotech, pharmaceutical, medical device, diagnostics, laboratory, digital health, and life sciences manufacturing companies located in or around Cambridge, Boston, Waltham, Watertown, Lexington, Somerville, and the broader Massachusetts life sciences corridor.
Potential MLSC incentives may include the life sciences investment tax credit, FDA user fees credit, extension of net operating losses, refundability of certain excess Massachusetts research credits, the Massachusetts life sciences research credit, deduction for qualified orphan drug expenses, designation as an R&D company for sales tax purposes, sales tax exemptions for certain property, and the life sciences jobs incentive refundable credit.
For life sciences companies hiring employees, expanding laboratory operations, purchasing research equipment, investing in R&D, paying FDA user fees, or building manufacturing capacity in Massachusetts, these incentives may be worth reviewing together with the federal R&D tax credit and Massachusetts research credit.
Companies should also understand the compliance requirements. MLSC tax incentives may require job creation commitments, annual reporting, and continued compliance with the terms of the award. If a company does not meet the required targets, incentives may be subject to reduction, revocation, or recapture.
In addition to tax incentives, MLSC offers other programs that may be relevant to life sciences companies, research organizations, and employers, including programs related to research infrastructure, equipment, internships, workforce development, early-stage research, biomanufacturing, medtech, and advanced manufacturing.
Startup Payroll Tax Offset and Research Expense Planning
For qualified small businesses, the R&D credit may be used to offset certain employer payroll taxes instead of only income taxes. This can be valuable for early-stage biotech and life sciences companies that are investing in research before generating taxable income.
R&D credit planning should also be coordinated with the tax treatment of research and experimental expenditures. Research expense rules can affect how life sciences companies deduct, capitalize, or amortize research costs for federal tax purposes. Companies should review how domestic and foreign research costs are being treated on the tax return.
Reviewing Your R&D Credit Opportunity
If a company is developing a drug candidate, designing a medical device, improving a formulation, conducting technical testing, performing laboratory research, or investing in scientific experimentation, it may be worth reviewing whether federal or state R&D tax credits apply.
Properly identifying and documenting qualified research activities can help life sciences companies support tax filings, improve cash flow, and maintain stronger records for investors, lenders, and future due diligence.
Federal and state tax credit opportunities for biotech, pharmaceutical, medical device, laboratory, and life sciences companies in the Greater Boston and Cambridge life sciences market.
Innovation in the life sciences industry can be expensive. In the Boston-Cambridge biotech ecosystem, companies may spend significant amounts on research programs, laboratory work, preclinical studies, clinical trials, product development, medical device design, regulatory testing, formulations, compounds, biologics, and proprietary scientific processes before revenue is ever generated.
The federal Research & Development Tax Credit was designed to encourage businesses to invest in new or improved products, processes, formulas, techniques, inventions, and technology. For life sciences companies, this may include qualified activities related to drug development, medical devices, diagnostics, laboratory testing, formulations, manufacturing processes, and technical experimentation.
Why the R&D Tax Credit Matters
The R&D tax credit can provide a dollar-for-dollar reduction of federal income tax. For eligible startups and qualified small businesses, a portion of the credit may also be available to offset certain employer payroll taxes. This can be especially valuable for early-stage life sciences companies that are investing heavily in research and development before becoming profitable.
The credit is not limited to successful projects. Failed experiments, abandoned compounds, rejected designs, unsuccessful prototypes, inconclusive testing, and technical alternatives may still be relevant when the company is attempting to resolve technical uncertainty through a process of experimentation.
R&D Tax Credits for Biotech and Life Sciences Companies
Biotech and life sciences companies often perform activities that may need to be reviewed for potential R&D credit opportunities. These may include developing new drug candidates, improving formulations, testing biologics, designing medical devices, developing diagnostics, improving laboratory methods, refining manufacturing processes, or evaluating technical alternatives.
The key issue is whether the work involves technical uncertainty and experimentation. A company may be uncertain about formulation, stability, performance, reliability, dosage, delivery method, safety, scalability, manufacturing process, testing method, or technical approach.
Routine quality control, ordinary testing, cosmetic changes, and non-technical business research generally do not qualify by themselves. However, testing performed as part of technical experimentation may be relevant.
Companies That May Benefit
A life sciences company may be a good candidate for an R&D credit review if it is involved in drug discovery, drug development, biologics, compounds, formulations, medical device design, diagnostics, preclinical studies, clinical trial support, regulatory testing, technical validation, laboratory methods, process development, or manufacturing scale-up.
Qualified Research Expenses
Qualified research expenses may include more than many companies expect. Depending on the facts, eligible costs may include employee wages for scientists, researchers, engineers, lab personnel, and technical supervisors performing, supervising, or supporting qualified research.
Other potential costs may include supplies used in experimentation, prototypes, testing materials, certain contract research expenses, laboratory testing, outside scientific consultants, CRO costs, and technical development costs connected to qualified research.
The key is not simply whether the company has an “R&D” account on its profit and loss statement. The key is whether the underlying activities meet the tax rules and whether the expenses can be reasonably supported.
Documentation and Project Tracking
Documentation is especially important for life sciences companies. Companies should be able to support what projects were worked on, what technical uncertainties existed, what experimentation was performed, who performed the work, and what costs were incurred.
Useful records may include project summaries, lab notebooks, payroll records, time allocations, general ledger detail, contractor invoices, CRO agreements, study protocols, testing results, formulation records, regulatory submissions, board reports, investor materials, and management summaries.
Federal and State R&D Credit Opportunities
In addition to the federal R&D tax credit, many states offer their own research and development credits or related incentives. This can be important for life sciences companies with research teams, laboratories, clinical activity, employees, or contractors in multiple states.
Massachusetts is especially important because of its concentration of biotech, pharmaceutical, medical device, laboratory, and life sciences companies in the Greater Boston and Cambridge market. Companies performing qualified research in Massachusetts may need to review whether a Massachusetts research credit opportunity exists.
Other states where R&D credit planning may be relevant include California, New York, New Jersey, Pennsylvania, Texas, Illinois, and other states where qualified research activities are performed.
Massachusetts Life Sciences Center Tax Incentives
For biotech and life sciences companies operating in the Greater Boston and Cambridge market, Massachusetts state incentives should be part of the tax planning discussion. The Massachusetts Life Sciences Center, commonly referred to as MLSC, administers programs designed to support life sciences research and development, commercialization, manufacturing, job creation, and long-term growth in Massachusetts.
The MLSC Tax Incentive Program supports companies engaged in life sciences research and development, commercialization, and manufacturing in Massachusetts. The program is designed to encourage companies of all sizes to expand in Massachusetts by creating new, long-term jobs.
More information is available directly from the Massachusetts Life Sciences Center at:
https://www.masslifesciences.com/programs/tax-incentive/
These incentives are not automatic. Companies generally must apply through MLSC, become certified as a life sciences company, meet program requirements, and receive an award before claiming the incentive. The program may be especially relevant for biotech, pharmaceutical, medical device, diagnostics, laboratory, digital health, and life sciences manufacturing companies located in or around Cambridge, Boston, Waltham, Watertown, Lexington, Somerville, and the broader Massachusetts life sciences corridor.
Potential MLSC incentives may include the life sciences investment tax credit, FDA user fees credit, extension of net operating losses, refundability of certain excess Massachusetts research credits, the Massachusetts life sciences research credit, deduction for qualified orphan drug expenses, designation as an R&D company for sales tax purposes, sales tax exemptions for certain property, and the life sciences jobs incentive refundable credit.
For life sciences companies hiring employees, expanding laboratory operations, purchasing research equipment, investing in R&D, paying FDA user fees, or building manufacturing capacity in Massachusetts, these incentives may be worth reviewing together with the federal R&D tax credit and Massachusetts research credit.
Companies should also understand the compliance requirements. MLSC tax incentives may require job creation commitments, annual reporting, and continued compliance with the terms of the award. If a company does not meet the required targets, incentives may be subject to reduction, revocation, or recapture.
In addition to tax incentives, MLSC offers other programs that may be relevant to life sciences companies, research organizations, and employers, including programs related to research infrastructure, equipment, internships, workforce development, early-stage research, biomanufacturing, medtech, and advanced manufacturing.
Startup Payroll Tax Offset and Research Expense Planning
For qualified small businesses, the R&D credit may be used to offset certain employer payroll taxes instead of only income taxes. This can be valuable for early-stage biotech and life sciences companies that are investing in research before generating taxable income.
R&D credit planning should also be coordinated with the tax treatment of research and experimental expenditures. Research expense rules can affect how life sciences companies deduct, capitalize, or amortize research costs for federal tax purposes. Companies should review how domestic and foreign research costs are being treated on the tax return.
Reviewing Your R&D Credit Opportunity
If a company is developing a drug candidate, designing a medical device, improving a formulation, conducting technical testing, performing laboratory research, or investing in scientific experimentation, it may be worth reviewing whether federal or state R&D tax credits apply.
Properly identifying and documenting qualified research activities can help life sciences companies support tax filings, improve cash flow, and maintain stronger records for investors, lenders, and future due diligence.